Valiltramiprosate lowers plasma p-tau217 levels in early Alzheimer's disease

Valiltramiprosate, a drug in development as a disease-modifying therapy for Alzheimer’s disease, showed rapid and sustained reduction of plasma p-tau217, among other clinical benefits, according to data from the developer.Valiltramiprosate (ALZ-801, Alzheon) is taken orally and acts as a small-molecule inhibitor of amyloid oligomer formation, according to information presented at